0001053369 false 0001053369 2023-09-25 2023-09-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares















September 25, 2023

Date of Report (Date of earliest event reported)



(Exact name of registrant as specified in its charter)


Nevada   001-15697   22-3542636
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)


165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)


(201) 750-2646

(Registrant’s telephone number, including area code)




(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ELTP   OTCQB







Item 7.01 Regulation FD Disclosure.


On September 25, 2023, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration for a generic version of an undisclosed generic drug product in a class of medications called opiate analgesics.


A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.   Description
99.1   Press Release dated September 25, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: September 25, 2023 ELITE PHARMACEUTICALS, INC.


  By: /s/ Nasrat Hakim
    Nasrat Hakim, President and CEO




Exhibit 99.1



Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product


NORTHVALE, N.J. – September 25, 2023 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics.


IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.


About Elite Pharmaceuticals, Inc.


Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.


This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.




Elite Pharmaceuticals, Inc.

Dianne Will, Investor Relations





Sep. 25, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 25, 2023
Entity File Number 001-15697
Entity Central Index Key 0001053369
Entity Tax Identification Number 22-3542636
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 165 Ludlow Avenue
Entity Address, City or Town Northvale
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07647
City Area Code (201)
Local Phone Number 750-2646
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ELTP
Entity Emerging Growth Company false

Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Elite Pharmaceuticals (QB) Charts.
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Elite Pharmaceuticals (QB) Charts.